Evaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatoses--a post marketing study.

Simple item page
dc.contributor.authorSavant, Sen_US
dc.contributor.authorJanaki, V Ren_US
dc.contributor.authorMittal, R Ren_US
dc.contributor.authorSengupta, Sen_US
dc.contributor.authorDesai, Aen_US
dc.date.accessioned2000-04-04en_US
dc.date.accessioned2009-05-31T14:27:28Z
dc.date.available2000-04-04en_US
dc.date.available2009-05-31T14:27:28Z
dc.date.issued2000-04-04en_US
dc.description.abstractThe aim of the present post marketing study was to study the safety and efficacy of supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) in the treatment of infected dermatoses. For this purpose physicians from different parts of India were requested to keep the clinical records prospectively as per a specially designed proforma over a follow-up period of 7 days, whenever they prescribed supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) for local application, three times a day, to their patients having either primary infection complicated by dermatoses or dermatoses infected secondarily. From the analysis of 251 clinical records contributed by 27 physicians, it was evident that in clinical practice, supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) was found to be safe and very effective by physicians in the treatment of infected dermatoses in 94.8% of the patients. Similarly 92.4% of the patients reported more than 70% improvement in their symptoms after 7 days of treatment. No adverse effects were reported during the treatment period by any of the patients except worsening of skin lesions by one patient. Thus from this study, supirocin-B ointment (mupirocin 2% + betamethasone dipropionate 0.05%) seems to be safe and effective in the treatment of infected dermatoses.en_US
dc.description.affiliationDepartment of Skin & STD, Nanavati Hospital & Medical Research Centre, Mumbai.en_US
dc.identifier.citationSavant S, Janaki VR, Mittal RR, Sengupta S, Desai A. Evaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatoses--a post marketing study. Journal of the Indian Medical Association. 2000 Apr; 98(4): 194-5en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/102706
dc.language.isoengen_US
dc.source.urihttps://www.jimaonline.org.in/en_US
dc.subject.meshBetamethasone --administration & dosageen_US
dc.subject.meshDrug Combinationsen_US
dc.subject.meshHumansen_US
dc.subject.meshIndiaen_US
dc.subject.meshMupirocin --administration & dosageen_US
dc.subject.meshOintmentsen_US
dc.subject.meshProduct Surveillance, Postmarketingen_US
dc.subject.meshPyoderma --drug therapyen_US
dc.subject.meshStaphylococcal Skin Infections --drug therapyen_US
dc.subject.meshStreptococcal Infections --drug therapyen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleEvaluation of safety and efficacy of supirocin-B (mupirocin 2% + betamethasone dipropionate 0.05%) in infected dermatoses--a post marketing study.en_US
dc.typeEvaluation Studiesen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Indian Medical Association